Skip Navigation LinksHome > July 2013 - Volume 20 - Issue 7 > Spanish Menopause Society position statement: use of tibolo...
doi: 10.1097/GME.0b013e31827b18c5
Original Articles

Spanish Menopause Society position statement: use of tibolone in postmenopausal women

Mendoza, Nicolás MD, PhD1; Abad, Pedro MD, PhD2; Baró, Francesc MD, PhD3; Cancelo, Ma Jesús MD, PhD4; Llaneza, Plácido MD, PhD5; Manubens, Montserrat MD, PhD6; Quereda, Francisco MD, PhD7; Sánchez-Borrego, Rafael MD, PhD8

Collapse Box


Abstract: Tibolone is a drug with complex tissue-specific action that exhibits a combination of estrogenic, progestogenic, and slight androgenic activity. Its variable profile explains its clinical effects, depending on the target tissue where it is metabolized, its metabolites’ affinity for and potency in hormone receptors, and probable enzymatic activity modulation.

In recent reviews and clinical trials, the effectiveness of tibolone in alleviating different hot flush menopause symptoms, mainly in mood and sexuality disorders, has been noted. In Spain, tibolone is the most prescribed hormonal treatment, and one of the most common complaints among postmenopausal women is change in sexual drive. For such reason, a panel of experts from the Spanish Menopause Society met to develop usage recommendations based on the best evidence available.

© 2013 by The North American Menopause Society.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.